Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase
Abstract Background Casticin, an isoflavone compound extracted from the herb Fructus Viticis, has demonstrated anti-inflammatory and anticancer activities and properties. The aim of this study was to investigate the effects and mechanisms of casticin in nasopharyngeal carcinoma (NPC) cells and to de...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-12-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-019-1069-6 |
| _version_ | 1818390195265863680 |
|---|---|
| author | Jingxian Liu Jinghong Yang Yuhe Hou Zhenwei Zhu Jie He Hao Zhao Xidong Ye Dengke Li Zhaohui Wu Zhongxi Huang Bingtao Hao Kaitai Yao |
| author_facet | Jingxian Liu Jinghong Yang Yuhe Hou Zhenwei Zhu Jie He Hao Zhao Xidong Ye Dengke Li Zhaohui Wu Zhongxi Huang Bingtao Hao Kaitai Yao |
| author_sort | Jingxian Liu |
| collection | DOAJ |
| description | Abstract Background Casticin, an isoflavone compound extracted from the herb Fructus Viticis, has demonstrated anti-inflammatory and anticancer activities and properties. The aim of this study was to investigate the effects and mechanisms of casticin in nasopharyngeal carcinoma (NPC) cells and to determine its potential for targeted use as a medicine. Methods NPC cells were used to perform the experiments. The CCK‑8 assay and colony formation assays were used to assess cell viability. Flow cytometry was used to measure the cell cycle and apoptosis analysis (annexin V/PI assay). A three-dimensional (3D) tumour sphere culture system was used to characterize the effect of casticin on NPC stem cells. In silico molecular docking prediction and high-throughput KINOME scan assays were used to evaluate the binding of casticin to phosphoinositide 3-kinase (PI3K), including wild-type and most of mutants variants. We also used the SelectScreen assay to detect the IC50 of ATP activity in the active site of the target kinase. Western blotting was used to evaluate the changes in key proteins involved cell cycle, apoptosis, stemness, and PI3K/protein kinase B (AKT) signalling. The effect of casticin treatment in vivo was determined by using a xenograft mouse model. Results Our results indicate that casticin is a new and novel selective PI3K inhibitor that can significantly inhibit NPC proliferation and that it induces G2/GM arrest and apoptosis by upregulating Bax/BCL2 expression. Moreover, casticin was observed to affect the self-renewal ability of the nasopharyngeal carcinoma cell lines, and a combination of casticin with BYL719 was observed to induce a decrease in the level of the phosphorylation of mTORC1 downstream targets in BYL719-insensitive NPC cell lines. Conclusion Casticin is a newly emerging selective PI3K inhibitor with potential for use as a targeted therapeutic treatment for nasopharyngeal carcinoma. Accordingly, casticin might represent a novel and effective agent against NPC and likely has high potential for combined use with pharmacological agents targeting PI3K/AKT. |
| first_indexed | 2024-12-14T04:53:46Z |
| format | Article |
| id | doaj.art-b1424010880c46c7b4cd96a5b1fa85f1 |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-12-14T04:53:46Z |
| publishDate | 2019-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-b1424010880c46c7b4cd96a5b1fa85f12022-12-21T23:16:28ZengBMCCancer Cell International1475-28672019-12-0119111610.1186/s12935-019-1069-6Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinaseJingxian Liu0Jinghong Yang1Yuhe Hou2Zhenwei Zhu3Jie He4Hao Zhao5Xidong Ye6Dengke Li7Zhaohui Wu8Zhongxi Huang9Bingtao Hao10Kaitai Yao11Guangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityGuangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityGuangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityGuangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityGuangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityGuangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityGuangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityGuangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityGuangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityGuangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityGuangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityGuangdong Provincial Key Laboratory of Tumor Immunotherapy, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical UniversityAbstract Background Casticin, an isoflavone compound extracted from the herb Fructus Viticis, has demonstrated anti-inflammatory and anticancer activities and properties. The aim of this study was to investigate the effects and mechanisms of casticin in nasopharyngeal carcinoma (NPC) cells and to determine its potential for targeted use as a medicine. Methods NPC cells were used to perform the experiments. The CCK‑8 assay and colony formation assays were used to assess cell viability. Flow cytometry was used to measure the cell cycle and apoptosis analysis (annexin V/PI assay). A three-dimensional (3D) tumour sphere culture system was used to characterize the effect of casticin on NPC stem cells. In silico molecular docking prediction and high-throughput KINOME scan assays were used to evaluate the binding of casticin to phosphoinositide 3-kinase (PI3K), including wild-type and most of mutants variants. We also used the SelectScreen assay to detect the IC50 of ATP activity in the active site of the target kinase. Western blotting was used to evaluate the changes in key proteins involved cell cycle, apoptosis, stemness, and PI3K/protein kinase B (AKT) signalling. The effect of casticin treatment in vivo was determined by using a xenograft mouse model. Results Our results indicate that casticin is a new and novel selective PI3K inhibitor that can significantly inhibit NPC proliferation and that it induces G2/GM arrest and apoptosis by upregulating Bax/BCL2 expression. Moreover, casticin was observed to affect the self-renewal ability of the nasopharyngeal carcinoma cell lines, and a combination of casticin with BYL719 was observed to induce a decrease in the level of the phosphorylation of mTORC1 downstream targets in BYL719-insensitive NPC cell lines. Conclusion Casticin is a newly emerging selective PI3K inhibitor with potential for use as a targeted therapeutic treatment for nasopharyngeal carcinoma. Accordingly, casticin might represent a novel and effective agent against NPC and likely has high potential for combined use with pharmacological agents targeting PI3K/AKT.https://doi.org/10.1186/s12935-019-1069-6CasticinNasopharyngeal carcinomaTargetPI3K/AKT pathway |
| spellingShingle | Jingxian Liu Jinghong Yang Yuhe Hou Zhenwei Zhu Jie He Hao Zhao Xidong Ye Dengke Li Zhaohui Wu Zhongxi Huang Bingtao Hao Kaitai Yao Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase Cancer Cell International Casticin Nasopharyngeal carcinoma Target PI3K/AKT pathway |
| title | Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase |
| title_full | Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase |
| title_fullStr | Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase |
| title_full_unstemmed | Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase |
| title_short | Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase |
| title_sort | casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3 kinase |
| topic | Casticin Nasopharyngeal carcinoma Target PI3K/AKT pathway |
| url | https://doi.org/10.1186/s12935-019-1069-6 |
| work_keys_str_mv | AT jingxianliu casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase AT jinghongyang casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase AT yuhehou casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase AT zhenweizhu casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase AT jiehe casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase AT haozhao casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase AT xidongye casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase AT dengkeli casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase AT zhaohuiwu casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase AT zhongxihuang casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase AT bingtaohao casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase AT kaitaiyao casticininhibitsnasopharyngealcarcinomagrowthbytargetingphosphoinositide3kinase |